The association between MTHFR 677C>T genotype and folate status and genomic and gene-specific DNA methylation in the colon of individuals without colorectal neoplasia1–4

Joanna Hanks, Iyeman Ayed, Neil Kukreja, Chris Rogers, Jessica Harris, Alina Gheorghiu, Chee Ling Liu, Peter Emery, and Maria Pufulete

ABSTRACT

Background: Decreased genomic and increased gene-specific DNA methylation predispose to colorectal cancer. Dietary folate intake and the methylenetetrahydrofolate reductase polymorphism (MTHFR 677C>T) may influence risk by modifying DNA methylation.

Objective: We investigated the associations between MTHFR 677C>T genotype, folate status, and DNA methylation in the colon.

Design: We conducted a cross-sectional study of 336 men and women (age 19–92 y) in the United Kingdom without colorectal neoplasia. We obtained blood samples for measurement of serum and red blood cell folate, plasma homocysteine, and MTHFR 677C>T genotype and colonic tissue biopsies for measurement of colonic tissue folate and DNA methylation (genomic- and gene-specific, estrogen receptor 1, ESR1; myoblast determination protein 1, MYOD1; insulin-like growth factor II, IGF2; tumor suppressor candidate 33, N33; adenomatous polyposis coli, APC; mut-L homolog 1, MLH1; and O6-methylguanine-DNA methyltransferase, MGMT) by liquid chromatography/electrospray ionization mass spectrometry and pyrosequencing, respectively.

Results: Of the 336 subjects recruited, 185 (55%) carried the CC, 119 (35%) the CT, and 32 (10%) the TT alleles. No significant differences in systemic markers of folate status and colonic tissue folate between genotypes were found. The MTHFR TT genotype was not associated with genomic or gene-specific DNA methylation. Biomarkers of folate status were not associated with genomic DNA methylation. Relations between biomarkers of folate status and gene-specific methylation were inconsistent. However, low serum folate was associated with high MGMT methylation (P = 0.001).

Conclusion: MTHFR 677C>T genotype and folate status were generally not associated with DNA methylation in the colon of a folate-replete population without neoplasia. This trial was registered at clinicaltrials.gov as ISRCTN43577261.

INTRODUCTION

There is conflicting evidence regarding the role of folate in colorectal cancer. Meta-analyses of cohort studies generally point to a negative association between folate intake and risk (1–3). More recently, 2 US cohorts reporting postfortification dietary folate intakes showed significant negative associations (4, 5), whereas another US cohort showed no effect (6). Results from randomized controlled trials investigating whether folic acid supplementation decreases the risk of colorectal adenoma (precursor of colorectal cancer) are largely negative (7–10), although the follow up of these trials has been probably too short to result in changes in risk of colorectal cancer, which develops over decades.

Folate provides one-carbon units for DNA methylation and DNA synthesis, and disruption in both of these processes is the hallmark of neoplasia. Modifications to DNA methylation occur on a genomic- and gene-specific level in colorectal neoplasia: a decrease in genomic DNA methylation (hypomethylation) (11) is accompanied by an increase in methylation of CpG islands in the promoter regions of many tumor-suppressor genes (hypermethylation) (12, 13).

It is uncertain whether folate status influences DNA methylation in the colon. Some reports have suggested associations between serum and red blood cell folate and genomic DNA methylation in people with and without neoplasia (14, 15), whereas others found none (16). One study found a positive association between red blood cell folate and hypermethylation of estrogen receptor 1 (ESR1)5 and secreted frizzled-related protein 1 (SFRP1) genes in the colon of subjects with adenoma.

1 From the Diabetes and Nutritional Sciences Division, King’s College London, London, United Kingdom (J Hanks, IA, NK, AG, CLL, PE, and MP), and the Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom (CR, J Harris, and MP).

2 PE and MP are both senior authors of the article.

3 Supported by the Biotechnology and Biological Sciences Research Council (BB/D523178/1). This is an open access article distributed under the CC-BY license (http://creativecommons.org/licenses/by/3.0/).

4 Address correspondence to M Pufulete, Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Queen’s Building, Bristol BS2 8WH, United Kingdom.

E-mail: maria.pufulete@bristol.ac.uk.

5 Abbreviations used: APC, adenomatous polyposis coli; ESR1, estrogen receptor 1; IGF2, insulin-like growth factor II; LINE-1, long interspersed nuclear element-1; MGMT, O6-methylguanine-DNA methyltransferase; MLH1, mut-L homolog 1; MTHFR, methylenetetrahydrofolate reductase; MYOD1, myoblast determination protein 1; N33, tumor suppressor candidate 33; PCR, polymerase chain reaction; QC, quality control; SFRP1, secreted frizzled-related protein 1.

Received February 28, 2013. Accepted for publication September 5, 2013. First published online October 9, 2013; doi: 10.3945/ajcn.113.061432.
the key enzyme methylenetetrahydrofolate reductase (MTHFR) (18). Folic acid intervention trials in individuals with adena have reported equally mixed results, with some suggesting that supplementation can reverse genomic DNA hypomethylation in the colon (19, 20) and others showing no effect on gene-specific methylation (17, 21).

The common 677C>T polymorphism in the gene encoding the key enzyme methylenetetrahydrofolate reductase (MTHFR) provides an additional factor that could modify associations between folate status and DNA methylation in the colon. Although associated with a lower risk of colorectal cancer (22), the exact interaction of this polymorphism with DNA methylation in the colon is not known, although interactions with folate status and genomic DNA methylation in leukocytes have been reported (23, 24).

The current study was designed to assess the association between the MTHFR 677C>T polymorphism, markers of folate status, and genomic- and gene-specific DNA methylation in the colon of subjects without colorectal neoplasia. We investigated gene-specific DNA methylation in 7 tumor suppressor genes: ESR1, myoblast determination protein 1 (MYOD1), insulin-like growth factor II (IGF2), tumor suppressor candidate 33 (N33), adenomatous polyposis coli (APC), MLH1, and O6-methylguanine-DNA methyltransferase (MGMT). These genes were selected because they all show increased methylation and silencing in colorectal tumors (25), and some also show age-related increases in methylation in the normal colonic mucosa of individuals with and without colorectal neoplasia (18, 26–30).

SUBJECTS AND METHODS

Study population

Subjects were patients (>18 y of age with no upper age limit) who were referred for a clinically indicated colonoscopy at the Endoscopy Departments at King’s College Hospital and Guy’s and St Thomas’ Hospital NHS Foundation Trusts between December 2006 and February 2009. Subjects were eligible for inclusion if they had a normal colonoscopy (to the ileo-caecal valve) with no macroscopic evidence of colorectal tumors (polyps or cancer) or inflammation. Subjects were excluded if they had any of the following: tumors at current colonoscopy; a strong family history of colorectal cancer as defined in the British Society of Gastroenterology guidelines (one first-degree relative with colorectal cancer younger than 45 y; 2 first-degree relatives with colorectal cancer; a family history of endometrial cancer; and St Thomas’ Hospital NHS Foundation Trust, London. Liver function was determined by using the evacuated tube technique (red top containing no anticoagulant for serum folate and vitamin B-12 and liver function tests and purple top containing EDTA for full blood count, red blood cell folate, plasma homocysteine, and DNA extraction). The EDTA-treated samples for plasma homocysteine were chilled on ice. Blood samples were spun within 2 h of collection; serum and plasma were stored at −80°C until assayed. At the end of colonoscopy, 6 mucosal biopsies were removed from the rectum (~12 cm from the anal verge) and immediately snap-frozen in liquid nitrogen. Of these, only 4 biopsies were available for use in the current study. After colonoscopy, subjects were given a food-frequency questionnaire (31) designed to assess dietary folate intake to take home and complete; they were asked to return the completed food-frequency questionnaire in the stamped addressed envelope provided.

Sample size and primary endpoints

The primary endpoints were differences in genomic- and gene-specific DNA methylation between the MTHFR 677C>T genotypes (CC, CT, and TT). Because there are no data on differences in gene-specific methylation between genotypes, sample size was calculated by using data from a previous observational study in which leukocyte DNA methylation was measured in healthy volunteers (24). On the basis of differences in genomic DNA methylation between CC and TT individuals in that study, a comparison between 32 TT individuals and 128 CC individuals would be adequate to detect a 50% difference (0.5 SD, 30 ng mCyt/μg DNA) in genomic DNA methylation between CC and TT individuals (5% significance level, 2 tailed, and 80% power; specifying the ratio of CC to TT as 4).

Biochemical analyses

Markers of folate status (serum and red blood cell folate and plasma homocysteine), serum vitamin B-12, and liver function variables were all measured in the Departments of Clinical Biochemistry and Haematology at King’s College Hospital NHS Trust, London. Liver function was determined by using the Advia 2400 Chemistry System (Siemens Health Care Diagnostics). The hematocrit (required to calculate red blood cell folate) was measured in fresh whole blood within 24 h of collection by using an ADVIA 2120 Hematology System (Siemens Health Care Diagnostics). Serum folate, vitamin B-12, red blood cell
folate, and plasma homocysteine were analyzed by competitive protein binding enzyme immunoassay with direct chemiluminescent technology on an Advia Centaur XP Immunoassay System (Siemens Health Care Diagnostics). For both folate and homocysteine assays, the within-run CV was <2.2% and the between-run CV was <5.2%.

Genotyping for the MTHFR 677C>T mutation

DNA was extracted from whole blood by using the GenElute Blood Genomic DNA Kit (Sigma-Aldrich). The DNA was quantified and assessed for purity by using the Nano Drop ND-1000 ultraviolet spectrophotometer (Thermo Scientific) and run on agarose gels to determine size (> 20 kb for all samples). The presence of the MTHFR 677C>T mutation was determined by DNA amplification with appropriate forward and reverse primers followed by Hinf I digestion of polymerase chain reaction (PCR) product as previously described (32).

Tissue folate analysis

Folate concentrations in colorectal biopsies were measured by standard microbiological assay with the use of Lactobacillus rhamnosus (ATCC 7469) (33). Briefly, tissue biopsies (5-64 mg) were weighed and homogenized (by crushing and shearing the sample in a standard Eppendorf tube with a polytetrafluoroethylene pestle until the sample was barely visible) in 20 volumes of folate extraction buffer [5 mmol β-mercaptoethanol/L and 0.1 mol sodium ascorbate/L in 0.1 mol bis(2-hydroxyethyl) imino-tris(hydroxymethyl) methane/L, pH 7.85] and immersed in boiling water for 20 min. The homogenate was cooled in an ice bath and centrifuged at 4°C, 2000 rpm, for 10 min. The supernatant fluid (1 mL) was transferred to sterile Eppendorf tubes and deconjugated with 1 mL chicken pancreas solution (5 mg/mL) and 3 mL 0.1 mol sodium phosphate buffer/L for 16 to 18 h at 37°C to convert polyglutamate folates to corresponding diglutamate derivatives. Deconjugated folate samples were incubated with L. rhamnosus on 96-well plates for 42 h at 37°C. Plates were read on a plate reader at 620 nm. Folate concentrations in the biopsies were calculated from a standard curve of folate concentrations in the biopsies were calculated from a standard curve of folate (Sigma-Aldrich) and folate (Sigma-Aldrich) were used as external standards. Quantification was carried out in multiple reaction monitoring mode by monitoring the precursor/product ion pair of m/z 228/112 for 2'-deoxycytidine and m/z 242/126 for 5-methyl-2'-deoxycytidine; the dwell time was 500s for each pair. The chromatographic peaks for 2'-deoxycytidine and 5-methyl-2'-deoxycytidine eluted at 5.0 and 6.5 min, respectively. Chromatograms were analyzed by using the Quanlynx v 4.1 software package.

The cytosine and 5-methylcytosine contents in DNA were calculated from calibration curves, where the area ratios of 2'-deoxycytidine or 5-methyl-2'-deoxycytidine to internal standard (labeled deoxycytidine) were plotted against known concentrations of 2'-deoxycytidine or 5-methyl-2'-deoxycytidine. The genomic DNA methylation status was expressed as the relative amount of 5-methyl-2'-deoxycytidine compared to total deoxycytidine residues (ie, % methylcytosine). The within- and between-day CVs (determined from QC samples assayed on the same day and on 12 different days) were 3.9% and 10.0%, respectively.

Gene-specific DNA methylation

Bisulfite modification of DNA (500 ng per sample) was carried out by using the EZ-96 DNA Methylation-Gold Kit (Zymo Research Corp) according to the manufacturer’s protocol. Bisulfite-modified DNA was stored at −20°C until used.

Promoter sequences were obtained from the ENSEMBL human genome database (http://www.ensembl.org/Homo_sapiens/Info/Index). Primers were designed by using the PSQ Assay Design Software (Qiagen) to amplify a maximum length of 200 bp of the selected 1000-bp sequence upstream of the promoter of each gene. Forward and reverse (biotinylated) primer sets (5’-3’) for each gene were as follows: ESR1 (GAGGTTGGAATTTGCTAGTTAGTTAGTGATGTT, CTTTAAATGAAAAACGCCCCCA); MYOD1...
by using 10 mL PCR product, which was loaded onto a 1.5% agarose gel. The gels were visualized by using ultraviolet transilluminator (Alpha Imager; Alpha Innotech CorpLP). Differences in categorical variables (sex, ethnic group, BMI, smoking, supplement use, and alcohol intake), biomarkers of folate status (serum, red blood cell and colonic tissue folate, and plasma homocysteine), \textit{MTHFR} 677C>T genotype, and genomic- and gene-specific DNA methylation was investigated by using Spearman’s rank correlation coefficients. The association between plasma homocysteine and demographic variables, biomarkers of folate status, serum vitamin B-12, and \textit{MTHFR} 677C>T genotype was assessed by using multiple linear regression. Plasma homocysteine was skewed, and no transformation improved the model fit; therefore, we performed the regression analysis after removing 4 outliers. Removal of these outliers did not change the conclusions.

Genomic- and gene-specific DNA methylation values are expressed as a proportion and are therefore bounded between 0 and 1. We assessed the association between genomic- and gene-specific methylation and biomarkers of folate status and \textit{MTHFR} 677C>T genotype by using generalized linear models with the binomial family distribution and logit link function, including the robust option to obtain robust SEs. The coefficient from the model gives the amount of change in the log odds of having high methylation for each unit increase in biomarkers of folate status. All models were adjusted for age (continuous), sex (male or female), ethnic group (white or nonwhite), supplement use (user or nonuser), and serum vitamin B-12 (continuous). For genomic DNA methylation, both unadjusted and adjusted models are presented. For gene-specific methylation, we presented only the adjusted models because the differences between adjusted and unadjusted models were marginal. For all models, we checked model fit visually using plots of residuals versus fitted values and versus each of the predictors in turn and normal QQ plots of standardized deviance residuals. We used \textit{Stata}’s \textit{lincom} command to check whether logit was the correct link function to use and assessed model fit by using the Hosmer and Lemeshow goodness-of-fit test and Pearson’s correlation test. For all models, results of these diagnostic tests suggested good model fit \((P > 0.05)\). We corrected for multiple comparisons \(8\) repeated analyses\) by using the Bonferroni correction to reduce the chance of obtaining false-positive results \(type\ I\ error\). We therefore considered a \(P\) value of 0.006 to be significant \(0.05/8\). All statistical tests were 2 sided. We repeated the analysis without adding supplement use to the models to prevent possible overadjustment \(because supplement use is clearly linked with the provision of B vitamins\). The results were not materially altered \(data not shown\). For gene-specific methylation, we presented coefficients and 95% CIs in graphic form for ease of interpretation.

### RESULTS

Of the 3112 patients screened, 295 did not consent to participate and 2466 did not meet the inclusion criteria, leaving a total of 351 eligible subjects. Of these, 4 had no blood biochemistry results and 11 had abnormal liver function tests; this
left a total of 336 participants for analysis (96% of those eligible). Of these, 185 (55%) were homozygous for the wild-type allele (CC) of the MTHFR 677C>T genotype, 119 (35%) carried one mutant allele (CT) and 32 (10%) were homozygous for the mutant allele (TT). Subject characteristics are shown in Table 1. There were no significant differences in age, BMI, folate or alcohol intakes, or the distribution of sex, smoking, and supplement use between genotypes. The distribution of white and black subjects differed between genotypes (white: 50% CC, 39% CT, and 11% TT; black: 72% CC, 23% CT, and 4% TT). Only 60 subjects (18%) returned the food-frequency questionnaire, hence dietary folate intakes were only available for these individuals.

The biomarkers of folate and vitamin B-12 status by MTHFR 677C>T genotype are shown in Table 2. There were no significant differences in serum, red cell and tissue folate, serum vitamin B-12 or plasma homocysteine between genotypes. Serum and red cell folate were positively correlated (\( r = 0.525, P < 0.001 \)); both were negatively correlated with plasma homocysteine (\( r = -0.309 \) and \( r = -0.261, P < 0.001 \), respectively). Tissue folate was positively correlated with serum and red cell folate (\( r = 0.464 \) and \( r = 0.292, P < 0.001 \)) and negatively correlated with plasma homocysteine (\( r = -0.140, P = 0.01 \)). There were no significant correlations between dietary folate intake and any of the biomarkers of folate status in the subset of subjects (\( n = 60 \)) who completed the food-frequency questionnaire (\( P > 0.05 \)). However, the use of supplements containing folic acid were significantly correlated with serum folate (\( P = 0.200, P < 0.001 \)), tissue folate (\( P = 0.121, P = 0.03 \)) and plasma homocysteine (\( P = -0.205, P < 0.001 \)), and weakly with red blood cell folate (\( P = 0.100, P = 0.08 \)).

Multiple linear regression analysis with plasma homocysteine as the dependent variable showed associations with age (\( P < 0.001 \)), sex (with higher homocysteine concentration in men, \( P < 0.001 \)), serum vitamin B-12 (\( P = 0.001 \)) and serum folate (\( P = 0.002 \)) but no association with MTHFR 677C>T genotype (\( P > 0.05 \)).

### Genomic DNA methylation

The average methylcytosine content of colonic DNA was 4.2% with a range of 1.5–6.8%. There was no influence of MTHFR 677C>T genotype on genomic DNA methylation (\( P = 0.60 \), Figure 1). There was no correlation between genomic DNA methylation and serum, red blood cell or tissue folate, serum vitamin B-12 or plasma homocysteine (all \( P \) values >0.05, data not shown). The coefficients and 95% CIs (adjusted and unadjusted) from generalized linear models for the association between genomic DNA methylation and biomarkers of folate status and MTHFR 677C>T genotype are shown in Table 3. In the adjusted model, there were no significant associations

---

**TABLE 1**

Subject characteristics by MTHFR 677C>T genotype

|                | CC (\( n = 185 \)) | CT (\( n = 119 \)) | TT (\( n = 32 \)) | \( P \) value |
|----------------|-------------------|-------------------|-----------------|--------------|
| Age (y)        | 57 (55, 59) \(^2\) | 57 (54, 60)       | 54 (48, 60)     | 0.58         |
| Sex [\( n \%] | Male              | 67 (36)           | 51 (43)         | 10 (31)      | 0.36         |
|                | Female            | 118 (64)          | 68 (57)         | 22 (69)      | 0.01\(^4\) |
| Ethnic group [\( n \%] | White           | 114 (62)          | 87 (73)         | 25 (78)      | 0.91\(^2\) |
|                | Black             | 50 (27)           | 16 (13)         | 3 (9)        | 0.001        |
|                | Asian             | 11 (6)            | 5 (4)           | 2 (6)        | 0.02         |
|                | Other             | 5 (3)             | 5 (4)           | 1 (3)        | 0.01         |
|                | Not recorded      | 5 (3)             | 6 (5)           | 1 (3)        | 0.01         |
| BMI (kg/m²)    | 26.9 (25.9, 28.0) | 26.7 (25.7, 27.7) | 27.6 (25.2, 29.9) | 0.80 |
| Smoking [\( n \%] | n                | 172               | 112             | 30           | 0.04         |
|                | Non smoker        | 132 (77)          | 87 (78)         | 20 (67)      | 0.44         |
|                | Smoker            | 40 (23)           | 25 (22)         | 10 (33)      | 0.03         |
| Supplement use [\( n \%] | n                | 168               | 111             | 30           | 0.04         |
|                | Non user          | 114 (68)          | 78 (70)         | 22 (73)      | 0.72         |
|                | User              | 54 (32)           | 33 (30)         | 8 (27)       | 0.55         |
| Folate-containing supplement use [\( n \%] | n                | 168               | 111             | 30           | 0.04         |
|                | Non user          | 145 (86)          | 94 (85)         | 26 (87)      | 0.72         |
|                | User              | 23 (14)           | 17 (15)         | 4 (13)       | 0.34         |
| Dietary folate intake (\( \mu g/d \)) | 327 (287, 366) | 376 (316, 436) | 370 (284, 455) | 0.21 |
| Total folate intake (diet + supplements) (\( \mu g/d \)) | 345 (297, 393) | 415 (335, 495) | 392 (322, 462) | 0.21 |
| Alcohol intake (g/d) | 1 (0–78)\(^2\) | 1 (0–103)        | 1 (0–64)        | 0.59         |

\(^2\) Differences between genotypes were tested by using chi-square tests (sex, smoking, and supplement use), ANOVA (age, BMI, and folate intake), and the Kruskal-Wallis test (alcohol intake).

\(^4\) Mean; 95% CI in parentheses (all such values).

\(^2\) The chi-square test was for white compared with black because of the limited number of subjects in the other groups.

\(^2\) Median; range in parentheses (all such values).
between any of the folate biomarkers or *MTHFR 677C>T* genotype and genomic DNA methylation. In the unadjusted model, a significant negative association was found between genomic DNA methylation and red blood cell folate (*P* = 0.04), but this disappeared after adjustment (*P* = 0.07).

### Gene-specific methylation

The median (range) methylation across all CpG sites analyzed for *ESR1*, *MYOD1*, *IGF2*, and *N33* were as follows: *ESR1*, 13% (1–40%); *MYOD1*, 10% (2–28%); *IGF2*, 8% (1–33%); and *N33*, 14% (3–67%). For *APC*, *MLH1*, and *MGMT*, the medians (ranges) were as follows: *APC*, 2% (0–7%); *MLH1*, 2% (0–31%); and *MGMT*, 2% (0–5%). *MLH1* had a small proportion of subjects (15%) with methylation values >10% (11–31%), but most (85%) had values between 0% and 10%.

*ESR1*, *N33*, and *MYOD1* methylation were positively associated with age (*ρ* = 0.373, *ρ* = 0.29, and *ρ* = 0.46, respectively; *P* < 0.001) and with each other (*ESR1* and *MYOD1*, *ρ* = 0.408; *ER* and *N33*, *ρ* = 0.247; *N33* and *MYOD1*, *ρ* = 0.233, *P* < 0.001). *IGF2*, *APC*, *MLH1*, and *MGMT* methylation were not associated with age (*P* > 0.05). *APC* methylation was positively associated with *IGF2* methylation (*ρ* = 0.117, *P* = 0.03) and *MGMT* methylation (*ρ* = 0.135, *P* = 0.01). *MLH1* methylation was positively associated with *ESR1* methylation (*ρ* = 0.110, *P* = 0.04). No association was found between genomic- and gene-specific DNA methylation (*P* > 0.05).

Of the other demographic variables assessed, sex was associated with *IGF2* methylation (16% higher in men than in women; *P* = 0.02), ethnicity (white compared with nonwhite) was associated with *N33* methylation (5% higher in nonwhites; *P* = 0.04), and supplement use was associated with *APC* methylation (17% lower in users; *P* = 0.03). No other significant associations were noted. All subsequent statistical analyses were adjusted for age, sex, ethnic group, and supplement use.

Gene-specific methylation did not differ between CC, CT, and TT genotypes (Figure 2). The coefficients and 95% CIs for the association between gene-specific methylation and biomarkers of folate status and *MTHFR 677C>T* genotype, assessed by using generalized linear models (see Supplementary Tables 1 and 2 under “Supplemental data” in the online issue), are shown in Figure 3 (A–F). The TT genotype did not influence methylation in any of the genes investigated (Figure 3F). However, the CT genotype was associated with lower *N33* methylation (*P* = 0.02) and higher *MYOD1* methylation (*P* = 0.02) (Figure 3E), although these relations were not significant after the Bonferroni correction for multiple comparisons (which raised the threshold for significance to *P* = 0.006).

### DISCUSSION

In the current study, we investigated the association between *MTHFR 677C>T* genotype and biomarkers of folate status and genomic and gene-specific methylation in the colon in 336 subjects without colorectal neoplasia. This population was replete with regards to folate and vitamin B-12 status. The distribution of the *MTHFR* T allele (35% CT and 10% TT) in our population was in Hardy-Weinberg equilibrium (*χ²* = 3.80).

The *MTHFR* TT genotype was not associated with either genomic- or gene-specific methylation in the colon. This result confirms our previous finding of no association between the *MTHFR* TT genotype and either genomic- (15) or gene-specific (18) DNA methylation in the colon in a smaller sample of subjects without neoplasia (68 and 73 subjects, respectively). Although

A positive association was found between red blood cell folate and *N33* methylation (*P* = 0.04) (Figure 3B), a negative association between serum (Figure 3A) and tissue (Figure 3C) folate and *MGMT* methylation (*P* = 0.001 and *P* = 0.01, respectively), and a positive association between plasma homocysteine and *MLH1* methylation (*P* = 0.02) (Figure 3D). Of these associations, only that between *MGMT* methylation and serum folate (*P* = 0.001) remained significant after Bonferroni correction. No other significant associations were noted.

### TABLE 2

| Biomarkers of folate and vitamin B-12 status by *MTHFR 677C>T* genotype | CC (n = 185) | CT (n = 119) | TT (n = 32) | *P* value |
|---|---|---|---|---|
| Serum folate (nmol/L) | 26.1 (7.5–54.4) | 24.5 (2.5–54.4) | 25.4 (8.6–54.4) | 0.43 |
| Red blood cell folate (nmol/L) | 977 (372–2234) | 927 (406–1752) | 969 (605–2982) | 0.44 |
| Colonic tissue folate (nmol/g tissue) | 0.89 (0.14–7.53) | 0.88 (0.10–7.34) | 0.90 (0.10–5.41) | 0.91 |
| Serum vitamin B-12 (pmol/L) | 314 (89–1476) | 315 (137–1117) | 285 (123–662) | 0.51 |
| Plasma homocysteine (µmol/L) | 15.6 (1.2–57.0) | 16.2 (2.6–41.9) | 17.8 (5.9–59.4) | 0.27 |

1 All values are medians; ranges in parentheses.

2 Kruskal-Wallis tests were used to test for differences between genotypes.
Plasma homocysteine (repletion (40, 41). It is possible that an association between levels of genomic DNA methylation (24, 42) or show greater lymphocytes (24, 40–42), and TT individuals have lower the TT genotype does influence genomic DNA methylation in studies were folate replete. In subjects with poor folate status, subjects that have measured DNA methylation in lymphocyte and DNA methylation is confirmed by other studies in healthy cancer.

type and DNA methylation differs in subjects with and without neoplasia. In their study, the difference in genomic DNA methylation in lymphocytes between CC and TT individuals was observed only when serum folate was below the median (<12 nmol/L). In our study the median serum folate concentration was 25 nmol/L, which is more than double that reported by Friso et al (24). When we stratified our population using the cutoff value used by Friso et al, we observed a 26% decrease in genomic DNA methylation between CC and TT subjects in those with serum folate values <12 nmol/L, although the number of subjects was too small (12 CC and 2 TT) to allow a statistical comparison.

Another possible reason for the lack of association between the MTHFR TT genotype and DNA methylation in our study was the lack of differences in serum and red blood cell folate between genotypes. Although plasma homocysteine was 13% higher in TT individuals than in CC individuals, this difference was not statistically significant. Generally, although population studies have shown that plasma homocysteine is higher in TT individuals (43), this effect is modified by folate status—a high folate status is associated with a reduced effect of MTHFR 677C>T on homocysteine concentrations (44–46).

In our multiple linear regression analysis, age, sex, and serum folate had stronger effects on plasma homocysteine concentrations (P ≤ 0.01) than did MTHFR 677C>T genotype (P > 0.05).

The current study showed no association between folate biomarkers and genomic DNA methylation in colonic mucosa (Table 3) after adjustment for various factors. In the unadjusted model, red blood cell folate was negatively associated with genomic DNA methylation (ie, DNA becomes hypomethylated as red blood cell folate increases). This is contrary to our previous report in which we showed a weak positive association between serum and red blood cell folate and genomic DNA methylation (P = 0.07 and P = 0.08, respectively) in subjects without neoplasia (15). In that study, we used the methyl acceptance assay to measure DNA methylation, and, although studies using the methyl acceptance assay have shown associations between folate status

| TABLE 3 |
| Association between genomic DNA methylation in colonic mucosa, MTHFR 677C>T genotype, and biomarkers of folate status |
| Unadjusted coefficient (95% CI) | P 2 | Adjusted coefficient (95% CI) | P 2 |
| MTHFR 677C>T |
| CC (reference) | | | |
| CT | −0.0188 (−0.0570, 0.0194) | 0.33 | −0.0237 (−0.0639, 0.0165) | 0.25 |
| TT | −0.0204 (−0.0092, 0.0520) | 0.58 | −0.0241 (−0.0104, 0.0541) | 0.55 |
| Serum folate (nmol/L) | 0.0003 (−0.0010, 0.0015) | 0.70 | 0.0002 (−0.0012, 0.0169) | 0.75 |
| Red blood cell folate (nmol/L) | −0.0001 (−0.0001, 0.0000) | 0.04 | −0.0001 (−0.0001, 0.0000) | 0.07 |
| Colonic tissue folate (nmol/g tissue) | 0.0091 (−0.0175, 0.0337) | 0.50 | 0.0198 (−0.0007, 0.0403) | 0.06 |
| Plasma homocysteine (μmol/L) | 0.0008 (−0.0017, 0.0034) | 0.54 | 0.0009 (−0.0020, 0.0039) | 0.62 |

1 Generalized linear model with a logit link (the natural log of the odds: log(1 + P/kXk) = β0 + β1X1 + β2X2… βkXk). For the continuous predictor variables (biomarkers of folate status), the coefficient gives the amount of change in the log odds of having high methylation for each unit increase in the biomarker (ie, a positive coefficient suggests an increase in the odds, whereas a negative coefficient suggests a decrease in the odds of having high methylation with increasing biomarker concentration). For the categorical predictor variable (MTHFR 677C>T), the coefficient gives the log odds of having high methylation in the CT or TT genotype compared with individuals carrying the CC genotype.

2 Threshold for significance using Bonferroni correction for 8 repeated tests is P = 0.006.

3 Adjusted for age, sex (male or female), ethnicity (white or nonwhite), supplement use (user or nonuser), serum vitamin B-12, and MTHFR 677C>T genotype.

4 Adjusted for age, sex (male or female), ethnicity (white or nonwhite), supplement use (user or nonuser), and serum vitamin B-12.

33 and MYOD1 methylation, the relevance of this is not clear, particularly because this relation was not consistent and not significant after Bonferroni correction for multiple comparisons. Only 3 studies have investigated the association between MTHFR 677C>T genotype and DNA methylation, but in individuals with adenoma and cancer. Figueiredo et al (16) and Wallace et al (17) reported no association between MTHFR 677C>T genotype and long interspersed nuclear element-1 (LINE-1) methylation (a measure of genomic DNA methylation) and ESR1 and SFRP1 methylation, respectively, in the colonic mucosa of 388 subjects with previously resected colorectal adenoma. Iacopetta et al (34) measured LINE-1 methylation in the normal mucosa of 178 individuals with colorectal cancer and showed that individuals with the mutant alleles for both MTHFR 677C>T and A1298C (ie, the low-activity genotype 677TT/1298CC) had lower LINE-1 methylation than did those with a high-activity genotype (677CC/1298AA) (P = 0.03). It is possible that having 2 mutations exerts a stronger effect on DNA methylation than does either mutation in isolation or that the relation between MTHFR 677C>T genotype and DNA methylation differs in subjects with and without cancer.

Our finding of no association between MTHFR TT genotype and DNA methylation is confirmed by other studies in healthy subjects that have measured DNA methylation in lymphocyte DNA (35–39). As with our study population, subjects in these studies were folate replete. In subjects with poor folate status, the TT genotype does influence genomic DNA methylation in lymphocytes (24, 40–42), and TT individuals have lower levels of genomic DNA methylation (24, 42) or show greater increases in genomic DNA methylation in response to folate repletion (40, 41). It is possible that an association between MTHFR 677C>T genotype and DNA methylation in the colon is only evident in individuals with low folate status. Friso et al (24) investigated the interaction between folate status and MTHFR 677C>T genotype in determining genomic DNA methylation in 187CC and 105TT subjects. In their study, the difference in genomic DNA methylation in lymphocytes between CC and TT individuals was observed only when serum folate was below the median (<12 nmol/L). In our study the median serum folate concentration was 25 nmol/L, which is more than double that reported by Friso et al (24). When we stratified our population using the cutoff value used by Friso et al, we observed a 26% decrease in genomic DNA methylation between CC and TT subjects in those with serum folate values <12 nmol/L, although the number of subjects was too small (12 CC and 2 TT) to allow a statistical comparison.

Another possible reason for the lack of association between the MTHFR TT genotype and DNA methylation in our study was the lack of differences in serum and red blood cell folate between genotypes. Although plasma homocysteine was 13% higher in TT individuals than in CC individuals, this difference was not statistically significant. Generally, although population studies have shown that plasma homocysteine is higher in TT individuals (43), this effect is modified by folate status—a high folate status is associated with a reduced effect of MTHFR 677C>T on homocysteine concentrations (44–46).

In our multiple linear regression analysis, age, sex, and serum folate had stronger effects on plasma homocysteine concentrations (P ≤ 0.01) than did MTHFR 677C>T genotype (P > 0.05).

The current study showed no association between folate biomarkers and genomic DNA methylation in colonic mucosa (Table 3) after adjustment for various factors. In the unadjusted model, red blood cell folate was negatively associated with genomic DNA methylation (ie, DNA becomes hypomethylated as red blood cell folate increases). This is contrary to our previous report in which we showed a weak positive association between serum and red blood cell folate and genomic DNA methylation (P = 0.07 and P = 0.08, respectively) in subjects without neoplasia (15). In that study, we used the methyl acceptance assay to measure DNA methylation, and, although studies using the methyl acceptance assay have shown associations between folate status
Gene-specific DNA methylation by *MTHFR 677C>T* genotype. Boxes represent medians and IQRs; whiskers are the expected range. A: *ESR1, N33, MYOD1,* and *IGF2* methylation. B: *APC, MGMT,* and *MLH1* methylation (CC, n = 185; CT, n = 119; TT, n = 32). Kruskal-Wallis tests were used for comparison between genotypes (*ESR1*, *P* = 0.92; *N33*, *P* = 0.12; *MYOD1*, *P* = 0.24; *IGF2*, *P* = 0.77; *APC*, *P* = 0.45; *MGMT*, *P* = 0.68; *MLH1*, *P* = 0.89).

We found no significant associations between markers of folate status and methylation of *ESR1, MYOD1, IGF2,* and *APC* in the colon. For *N33, MGMT,* and *MLH1,* some associations were noted, although these were in opposite directions (increased methylation with higher red blood cell folate for *N33* and decreased methylation with higher serum and colonic folate for *MGMT*). The importance of these findings is not certain, given that these relations were not consistent, either between genes or for biomarkers within the same gene and all but one of these associations (*MGMT* methylation and serum folate) were not significant after correction for multiple comparisons. In our previous study, we found no relation between markers of folate status and *ESR1* and *MLH1* methylation in 73 subjects without colorectal neoplasia (15). Wallace et al (17) reported that higher red blood cell folate concentrations were associated with higher levels of *ESR1* (*P* = 0.03) and *SFRP1* (*P* = 0.01) methylation in normal colonic mucosa of subjects with adenoma, which suggests a negative effect of high folate status on gene-specific methylation. However, this study included subjects with previously resected adenomas who participated in a randomized controlled trial of folic acid supplementation (1 mg/d for 3 y) for the prevention of further adenomas. Individuals with adenoma may have different gene-specific methylation patterns in their normal mucosa than individuals who are neoplasia free [as has been shown previously (12, 15, 26)] and so may respond differently to increasing folate status, particularly when folic acid is administered in pharmacologic doses.

Our study had several strengths. We used a population without neoplasia, which avoided the potential confounding effects that neoplasia may have on DNA methylation. We also used quantitative assays with high sensitivity to assess genomic and gene-specific DNA methylation. We measured both systemic and tissue folate to allow a comprehensive assessment of the relation between folate status and DNA methylation. Colonic tissue folate was strongly associated with serum and red blood cell folate, so it appears that systemic markers of folate status are good surrogates of folate status in the colon. The limitations of our study include the fact that our population may not be representative of general population without neoplasia, because they presented with symptoms (eg, bleeding, change in bowel habit, pain, and bloating) that prompted referral for colonoscopy. These individuals may have different dietary habits and other factors that may have influenced DNA methylation in the colon. Another limitation is that none of the methylation assays were performed in duplicate because of the limited availability of colonic tissue biopsies. This may have influenced our findings in view of the variability in the methylation assays (7–10%). Also, we used rectal biopsies, but there is evidence that methylation levels differ between the left and right side of the colon (17).

In conclusion, the findings of the current study suggest that *MTHFR 677C>T* genotype and biomarkers of folate status do not influence DNA methylation in this population. The suggestion that a higher folate status is associated with lower *MGMT* methylation needs to be interpreted with caution given the inconsistencies across the folate measures and between different genes. Future studies need to examine these relations in populations with low folate status and examine the influence of other mutations in folate pathway genes on DNA methylation in the colon.

We thank LGC, UK, for providing their facilities and expertise for the genomic DNA methylation measurements in colorectal tissue. Supported by the Biotechnology and Biological Sciences Research Council (BB/D523178/1).

The authors’ responsibilities were as follows—MP: designed the study; J Hanks, IA, NK, AG, and CLL: conducted the research; J Harris, CR, and MP: analyzed the data; J Hanks, MP, and PE: wrote the manuscript; and MP...
FIGURE 3. Association between gene-specific methylation in colonic mucosa, biomarkers of folate status, and MTHFR 677C>T genotype. Dots and horizontal lines represent the coefficients and 95% CIs, respectively, obtained from generalized linear models adjusted for age, sex (male or female), ethnicity (white or nonwhite), supplement use (user or nonuser), serum vitamin B-12, and MTHFR 677C>T genotype. The coefficients give the amount of change in the log odds of having high methylation in each gene investigated for each unit increase in the independent variables (with all other variables held constant) serum folate (nmol/L) (A), red blood cell folate (nmol/L) (B), tissue folate (nmol/g tissue) (C), and plasma homocysteine (μmol/L) (D) or the log odds of having high methylation in individuals carrying the MTHFR CT genotype (E) or TT genotype (F) compared with individuals carrying the CC genotype. The vertical dotted line (coefficient of 0) shows the line of no effect. Coefficients >0 indicate an increased odds of having high methylation (positive association), whereas coefficients <0 indicate a decreased odds of having high methylation (negative association), for each unit increase in biomarker concentrations, or for the CT or TT genotype compared with the CC genotype (reference). The threshold for significance with Bonferroni correction for 8 repeated tests is $P = 0.006$. $1P = 0.001$ (significant after Bonferroni correction); $2P = 0.04$; $3P = 0.01$; $4P = 0.02$; $5P = 0.02$; $6P = 0.02$. 
and PE: had primary responsibility for the final content. None of the authors had a potential conflict of interest.

REFERENCES

1. Kennedy DA, Stern SJ, Moretti M, Matok I, Sarkar M, Nickel C, Koren G. Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. Cancer Epidemiol 2011;35:2–10.

2. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 2005;113:825–8

3. Kim DH, Smith-Warner SA, Spiegelman D, Yaun SS, Colditz GA, Freudenberg JL, Giovannucci E, Goldbohn RA, Graham S, Harnack L, et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control 2010;21:1919–30.

4. Gibson TM, Weinstein SJ, Pfeiffer RM, Hollenbeck AR, Subar AF, Schatzkin A, Mayne ST, Stolzenburg-Solomon R. Pre- and post-fortification intake of folate and risk of colorectal cancer in a large prospective cohort study in the United States. Am J Clin Nutr 2011;94:1053–62.

5. Stevens VL, McCullough ML, Sun J, Jacobs EJ, Campbell PT, Gaptstein SM. High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology 2011;141:98–105.

6. Zschaitz S, Cheng TY, Neuhauser ML, Zheng Y, Ray RM, Miller JW, Song X, Maneval DR, Bereford SA, Lane D, et al. Vitamin intake and incidence of colorectal cancer: results from the Women’s Health Initiative Observational Study cohort. Am J Clin Nutr 2013;97:332–43.

7. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29–38.

8. Wu K, Platz EA, Willett WC, Fuchs CS, Selhub J, Rosner BA, Hunter DJ, Giovannucci E. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009;90:1623–31.

9. Paspatis GA, Karamanolis DG. Folate supplementation and adenomatous colon polyyps. Dis Colon Rectum 1994;37:1340–1.

10. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2009;297:2351–9.

11. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187–90.

12. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148–59.

13. Isa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988–93.

14. Pufulete M, Al-Ghaisiemi R, Leather AJ, Appleby P, Gout S, Terry C, Emery PW, Sanders TA. Influence of folate status on genomic DNA methylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 2003;124:1240–8.

15. Pufulete M, Al-Ghaisiemi R, Rennie JA, Appleby P, Harris N, Gout S, Emery PW, Sanders TA. Methylation of the ESR1 CpG island in sporadic colorectal cancer is associated with increased risk of colorectal cancer development. Cancer Res 2001;61:6991–5.

16. McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, et al. Folic acid supplementation on genome wide methylation in colonic mucosa of subjects without colorectal adenoma or cancer. Br J Cancer 2006;94:593–8.

17. Figueiredo JC, Grau MV, Wallace K, Levine SJ, Shen L, Hamdan R, Chen X, Bresalier RS, McKeown-Eyssen G, Haile RW, et al. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev 2009;18:1041–9.

18. Wallach K, Grau MV, Levine SJ, Shen L, Hamdan R, Chen X, Gutt H, Haile RW, Barry EL, Ahnen D, et al. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev Res (Phila) 2010;3:1552–64.

19. G, Richter R, Fuchs CS, Selhub J, Rosner BA, Hunter DJ, Giovannucci E. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009;90:1623–31.

20. Pufulete M, Al-Ghaisiemi R, Khushal A, Appleby P, Harris N, Gout S, Emery PW, Sanders TA. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut 2005;54:648–53.

21. van den Donk M, Pellis L, Crott JW, van Engeland M, Friederich P, Nagenhag FM, van Bergeijk JD, de Boer SY, Mason JB, Kok FJ, et al. Folic acid and vitamin B12 supplementation does not favorably influence uracil incorporation and promoter methylation in rectal mucosa DNA of subjects with previous colorectal adenomas. J Nutr 2007;137:2114–20.

22. Taioli E, Garza MA, Ahn YO, Bishop DT, Bost J, Budai B, Chou K, Gemignani F, Keku T, Lima CS, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol 2009;170:1207–21.

23. Axume J, Smith SS, Pogribny IP, Moriarty DJ, Cuddil MA. The MTHFR 677TT genotype and folate intake interact to lower global leukocyte DNA methylation in young Mexican American women. Nutr Res 2007;27:1365–17.

24. Friso S, Choi SW, Grieve D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacobs PF, Rosenberg JH, Korocher R, et al. Common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002;99:5606–11.

25. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:6681–6.

26. Belshaw NJ, Elliott GO, Williams EA, Mathers JC, Buckley L, Bahari B, Robinson T. Methylation of the ESRI CpG island in the colorectal mucosa is an ‘all or nothing’ process in healthy human colon, and is accelerated by dietary folate supplementation in the mouse. Biochem Soc Trans 2005;33:709–11.

27. Deng G, Peng E, Gun J, Terdican M, Leischinger M, Kim YM. Methylation of hMLH1 promoter correlates with the gene silenceing with a region-specific manner in colorectal cancer. Br J Cancer 2002;86:574–9.

28. Kawakami K, Ruzskiwicz A, Bennett G, Moore G, Jrie F, Watanabe G, Iacopetta B. DNA hypermethylation the normal colorectal mucosa of patients with colorectal cancer. Br J Cancer 2006;94:593–8.

29. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW Jr, Salovaraa R, Aaltonen LA, de la Chapelle A. Age-related hypermethylation of the 5’ region of MLH1 in normal colorectal mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001;61:6991–5.

30. Shih Y, Kondo Y, Rokier GL, Xiao L, Hernandez NS, Vilaythong J, Houlahan PS, Krouse RS, Prasad AR, Einspahr JG, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330–8.

31. Pufulete M, Emery PW, Nelson M, Sanders TA. Validation of a short food frequency questionnaire to assess folate intake. Br J Nutr 2002;87:383–90.

32. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, Kooit Y, Rottier GL, Xiao L, Hernandez NS, Vilaythong J, Houlahan PS, Krouse RS, Prasad AR, Einspahr JG, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330–8.

33. Iacopetta B, Grieve D, Phillips M, Ruskiewicz A, Moore J, Minamoto T, Kawakami K. Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colorectal mucosa. Cancer Sci 2007;98:1544–60.

34. Narayanan S, McConnell J, Little J, Sharp L, Piyathilake CJ, Powers H, Gemignani F, Iacopetta B, Ruskiewicz M, Ruskiewicz A, Moore J, Minamoto T, Kawakami K. Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colorectal mucosa. Cancer Sci 2007;98:1544–60.

35. Fufulête M, Al-Ghaisiemi R, Khushal A, Appleby P, Harris N, Gout S, Emery PW, Sanders TA. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut 2005;54:648–53.
global methylation level of leukocyte DNA. Cancer Sci 2012;103:2159–64.

37. Kok RM, Smith DE, Barto R, Spijkerman AM, Teerlink T, Gellekink HJ, Jakobs C, Smulders YM. Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects. Clin Chem Lab Med 2007;45:903–11.

38. La Merrill M, Torres-Sanchez L, Ruiz-Ramos R, Lopez-Carrillo L, Cebrian ME, Chen J. The association between first trimester micronutrient intake, MTHFR genotypes, and global DNA methylation in pregnant women. J Matern Fetal Neonatal Med 2012;25:133–7.

39. Ulrich CM, Toriola AT, Koepf LM, Sandifer T, Poole EM, Duggan C, McTiernan A, Issa JP. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics 2012;7:1020–8.

40. Guinotte CL, Burns MG, Axume JA, Hata H, Urrutia TF, Alamilla A, McCabe D, Singgih A, Cogger EA, Caudill MA. Methylenetetrahydrofolate reductase 677C>T variant modulates folate status response to controlled folate intake in young women. J Nutr 2003;133:1272–80.

41. Shelnutt KP, Kauwell GP, Gregory JF 3rd, Maneval DR, Quinlivan EP, Theriaque DW, Henderson GN, Bailey LB. Methylenetetrahydrofolate reductase 677C>T polymorphism affects DNA methylation in response to controlled folate intake in young women. J Nutr Biochem 2004;15:554–60.

42. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2008;9:849–53.

43. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rosen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.

44. Chiuve SE, Giovannucci EL, Hankinson SE, Hunter DJ, Stampfer MJ, Willett WC, Rimm EB. Alcohol intake and methylenetetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine. Am J Clin Nutr 2005;82:155–62.

45. de Bree A, Verschuren WM, Bjerke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, Blom HJ. Effect of the methylenetetrahydrofolate reductase 677C>T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 2003;77:687–93.

46. Hustad S, Midttun O, Schneede J, Vollset SE, Grotmol T, Ueland PM. The methylenetetrahydrofolate reductase 677C>T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am J Hum Genet 2007;80:846–55.

47. Cravo M, Fidalgo P, Pereira AD, Gouveia-Oliveira A, Chaves P, Selhub J, Mason JB, Mira FC, Leitao CN. DNA methylation as an intermediate biomarker in colorectal cancer: modulation by folic acid supplementation. Eur J Cancer Prev 1994;3:473–9.

48. McGlynn AP, Wasson GR, O’Reilly SL, McNulty H, Downes CS, Chang CK, Hoey L, Molloy AM, Ward M, Strain JJ, et al. Low colonic folate is associated with uracil misincorporation and global DNA hypomethylation in human colorectum. J Nutr 2013;143:27–33.

49. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573–7.

50. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nut Genet 1994;7:536–40.